As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
With increased production and growing supplies, the company hopes to regain some of the momentum with Zostavax that was lost when production issues derailed plans in 2006.
Shingles can lead to post-herpetic pain and other issues in older people, and the vaccine, which halves the chance of severe attacks of shingles, is safe and well-tolerated in this group, a new study finds.
It has taken 6 years, but with a significant manufacturing expansion, Merck has gotten its issues addressed for its shingles vaccine Zostavax.
After manufacturing problems constricted supplies for several years, the U.S.-based drugmaker has filled back orders and restored ongoing supplies, clearing the way for a renewed sales push.
A paper presented to the American Academy of Dermatology looked at the effectiveness of a booster shot of a VZV vaccine.
Five years ago, Merck gained FDA approval for its shingles prevention vaccine Zostavax. The agency recently expanded that approval to adults 50 years and older. Yet vaccination rates remain low due
Three months after the CDC recommended all adults over the age of 60 receive Merck's Zostavax vaccine, the FDA has approved the shingles preventative for use in adults ages 50 to 59. The FDA approved
Some patients inoculated with Zostavax, Merck's shingles vaccine, shed the virus used for the vaccine through their saliva for one month after immunization, according to a researcher from the
Although shingles isn't cureable, a retrospective study has found that Merck's Zostavax vaccine can cut a person's risk of of developing the illness by 55 percent. It is the only shingles vax